Other studies either found no anti-inflammatory effects as assessed in sputum [9], or confirmed anti-inflammatory effects of three-month ICS treatment assessed in bronchial biopsies of COPD patients, including reductions in CD8+ lymphocytes, mast cells and macrophages [10]–[12]. This evidence concerns the gene CD8A and chronic obstructive pulmonary disease.